BioCentury
ARTICLE | Company News

CoCo Therapeutics neurology news

March 11, 2013 7:00 AM UTC

CoCo Therapeutics debuted earlier this month with undisclosed funding from Advent Venture Partners to develop retinoic acid receptor alpha (RARA) agonists to treat Alzheimer's disease. Founding Chairman Raj Parekh, general partner at Advent, said CoCo is conducting late-stage preclinical work of an undisclosed lead compound, but declined to say when the newco plans to start Phase I testing. ...